Introduction {#s1}
============

Cardiovascular disease (CVD) is the major cause of morbidity and mortality among persons with diabetes ([@B1]). However, substantial heterogeneity in CVD risk has been described among individuals with diabetes ([@B2]--[@B4]). As the incidence and prevalence of diabetes continue to rise worldwide, there is a compelling rationale for improving CVD risk prediction provided by commonly used markers of risk, such as traditional risk factors, abnormal electrocardiogram (ECG), and conventional measures of diabetes complications, in particular to identify persons at the lowest risk, who may derive less benefit from preventive measures, and those at highest risk, who may derive the greatest benefit.

Recently, the circulating cardiac biomarkers, including N-terminal prohormone brain natriuretic peptide (NTproBNP) and troponin T (TnT), have been proposed as predictors of adverse cardiovascular outcomes in the general population and among persons with diabetes ([@B5]--[@B12]). However, these prior studies of diabetes were limited in their assessment of event discrimination or examined clinical trial cohorts, which may lack applicability to the broader population. Furthermore, whether circulating cardiac biomarkers improve CVD risk prediction beyond that achieved not only with traditional risk factors but also with other risk markers routinely assessed in diabetes, such as ECG findings and conventional measures of diabetes complications, has not been specifically tested.

Therefore, among participants with prevalent diabetes in the Atherosclerosis Risk in Communities (ARIC) study, we hypothesized *1*) heterogeneity in the risk of incident CVD and *2*) enhancement of CVD risk prediction with NTproBNP and high-sensitivity TnT beyond commonly used markers of risk.

Research Design and Methods {#s2}
===========================

Study Population {#s3}
----------------

The ARIC study is an ongoing prospective observational study of the natural history of atherosclerotic diseases and cardiovascular risk factors. Detailed study rationale, design, and procedures have previously been published ([@B13]). The original cohort was recruited between 1987 and 1989 using probability sampling of middle-aged (45--64 years old) men and women from four communities in the U.S. (Forsyth County, NC; Jackson, MS; Minneapolis, MN; and Washington County, MD). Subsequent short-term follow-up visits occurred at 3-year intervals up to 1998, with annual telephone interviews conducted between visits and to the present. A fifth visit was completed in 2011--2013.

The fourth visit (1996--1998) is the baseline for the current study. The study population included participants without prevalent CVD, with further categorization according to the presence (*n* = 1,510) or absence (*n* = 6,892) of diabetes. Prevalent diabetes was defined according to *1*) fasting glucose ≥126 mg/dL or nonfasting glucose ≥200 mg/dL or *2*) use of hypoglycemic drugs or a reported physician diagnosis of diabetes at visit 4 or any prior visit ([@B14]). Although diabetes type has not been formally assessed in ARIC, approximately one-third of individuals in this study population were known to be diagnosed with diabetes at ARIC visit 1 (age 45--64 years), while 62% of our study population developed diabetes after visit 1. The known prevalence of type 1 versus type 2 diabetes suggests that the majority of the patients with diabetes at baseline would be classified with type 2 diabetes, and all patients diagnosed after baseline can be classified with type 2 diabetes, in keeping with previous publications from ARIC ([@B15]). Thus, the vast majority of our study sample comprised persons with type 2 diabetes. Prevalent CVD was defined as a prior history of coronary heart disease (CHD), heart failure (HF), and/or stroke according to previously published criteria ([@B16]--[@B19]). Anthropometric and demographic data, medical history, blood pressure, and lipid assessments were obtained at visit 4 as previously described ([@B20]).

Conventional measures of diabetes complications included retinopathy, nephropathy, and peripheral arterial disease (PAD). Retinopathy was evaluated via retinal photography during visit 3 (1993--1995) and was considered to be present if any characteristic lesion as defined by the Early Treatment Diabetic Retinopathy Study severity scale was present ([@B21]). Nephropathy was defined by an estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m^2^ or urine albumin-to-creatinine ratio (UACR) ≥30 mg/g ([@B22]). eGFR was calculated via the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine and cystatin C equation, using covariates obtained at visit 4. UACR was calculated from a random urine sample collected at visit 4 ([@B23]). PAD was assessed as previously described in ARIC ([@B24]) and included intermittent claudication determined from the Rose Questionnaire, PAD-related hospitalization by ICD-9 code, or ankle-brachial index (ABI) \<0.9 detected at visit 4 or at visit 3 (*n* = 365) or 1 (*n* = 302) if ABI at visit 4 was missing ([@B25]).

Major ECG abnormalities at visit 4 were defined according to the Minnesota coding system and ARIC study procedures as previously described ([@B26]) and included the presence of ventricular conduction defect, left ventricular hypertrophy, isolated major ST segment or T-wave (ST-T) wave abnormalities, or atrial fibrillation/flutter. Myocardial infarction (MI) by ECG was excluded, as it was part of the definition for prevalent CHD.

NTproBNP was measured from stored plasma samples collected from participants during visit 4, using an electrochemiluminescent immunoassay on an automated Cobas e411 analyzer (Roche Diagnostics) with a lower limit of detection ≤5 pg/mL and interassay coefficient of variation 3.5--4.7% ([@B27]). We dichotomized NTproBNP using a fixed cutoff value of 125 pg/mL as previously suggested ([@B28]).

TnT was measured using a high-sensitivity assay (hs-TnT), Elecsys Troponin T (Roche Diagnostics, Indianapolis, IN), with a lower limit of detection of 3 ng/L. TnT levels were categorized as abnormal based on the manufacturer's proposed 99th percentile in a healthy reference population (≥14 ng/L) ([@B29]), a value significantly lower than the 99th percentile detected in our population with diabetes (50 ng/L).

Of the 11,656 participants who attended visit 4, we initially determined status regarding prevalent diabetes (*n* = 2,936 with diabetes and *n* = 8,720 without diabetes). Among participants with prevalent diabetes, we excluded those with missing data on diabetes (*n* = 548) and participants with missing or prevalent HF, CHD, or stroke at visit 4 (*n* = 591), since for some clinical outcomes patients with prevalent disease were not followed up for postbaseline in ARIC. Additionally, we sequentially excluded those with ethnicity other than black or white (*n* = 5), underrepresented in ARIC, and those with missing data on cardiovascular risk factors (*n* = 123) and with missing data on conventional complications of diabetes or cardiac biomarkers (*n* = 159), leading to a final population of 1,510 subjects with diabetes. Similarly, from the group without prevalent diabetes, we excluded subjects with missing or prevalent HF, CHD, or stroke at visit 4; with ethnicity other than black or white; and with missing data on cardiovascular risk factors, leading to 6,892 subjects without diabetes.

Outcomes {#s4}
--------

The primary outcome was a composite of incident fatal or nonfatal CVD events, including CHD (definite fatal CHD, definite or probable MI, or coronary revascularization) ([@B16],[@B17]), HF (based on ICD-9 or -10 codes from hospital discharges or death certificates) ([@B18]), and/or stroke (validated definite or probable nonfatal stroke) ([@B19]). As a sensitivity analysis, we excluded coronary revascularization procedures from the composite outcome. Secondary end points included the individual component outcomes of incident CHD, HF, or stroke. The follow-up period was defined as the time elapsed from the date of visit 4 to 31 December 2011.

Statistical Analysis {#s5}
--------------------

The 1,510 participants with diabetes were categorized into four groups according to the presence or absence of conventional complications of diabetes, abnormal ECG, and/or abnormal levels of circulating cardiac biomarkers. Group I included participants with neither conventional complications of diabetes/abnormal ECG nor abnormal levels of circulating cardiac biomarkers (*n* = 725 \[48%\]). Group II comprised participants with at least one conventional complication of diabetes or abnormal ECG but negative circulating cardiac biomarkers (*n* = 356 \[24%\]). Group III included participants with at least one abnormal circulating cardiac biomarker but no conventional complications of diabetes or abnormal ECG (*n* = 186 \[12%\]), and group IV consisted of participants with abnormalities of both (*n* = 243 \[16%\]). Clinical characteristics were compared across these four groups. Right-skewed variables (triglycerides, UACR, and NTproBNP) were log transformed prior to analysis. Pack-years of cigarettes was log transformed after adding 1 to the observed value, such that nonsmokers were coded as 0 after transformation. Continuous variables were expressed as mean ± SD or median (25th, 75th percentiles) and compared with ANOVA, while categorical variables were compared using a χ^2^ test.

CVD incidence rates for each measure of diabetes complication, abnormal ECG, or cardiac biomarkers and within each of the four aforementioned categories were calculated. The risk of adverse cardiovascular outcomes was assessed with sequential Cox proportional hazards regression models. Our multivariate model comprised variables derived from well-known risk scores (Framingham risk model, UK Prospective Diabetes Study \[UKPDS\] risk engine, ARIC CHD risk score) ([@B30]--[@B32]), therapeutic strategies known to affect CVD risk in diabetes, and variables based on noted baseline differences between the groups and/or on prior literature ([@B33]--[@B35]). Model 1 was adjusted for age, sex, race, and field center. Model 2 was adjusted for variables in model 1 as well as smoking status, log-transformed pack-years of cigarettes (packs of cigarettes smoked per day times number of years smoked), BMI, waist-to-hip ratio, systolic blood pressure, hypertension medication use, lipid-lowering medication use, aspirin use, education level, total-to-HDL cholesterol ratio, log-transformed triglycerides, and duration of diabetes. (As a sensitivity analysis, we adjusted model 2 also for glycated hemoglobin, detected in ARIC at visit 2.) Model 3 was further adjusted for conventional measures of diabetes complications (retinopathy, nephropathy, PAD) and ECG abnormalities, while model 4 also included cardiac biomarkers (abnormal TnT and abnormal NTproBNP). We also assessed CVD incidence rates in participants without diabetes and compared CVD risk with that of the four groups of participants with diabetes while adjusting for variables included in model 2. Additionally, we performed a sensitivity analysis also considering carotid artery intima-media wall thickness (cIMT) as a conventional measure of diabetes complications, since previous studies have suggested that persons without known CVD with increased cIMT are at increased risk for cardiac events and stroke ([@B36]).

Using the Harrell *C* statistic, continuous net reclassification index (NRI), and integrated discrimination improvement (IDI) statistics ([@B37]), we assessed whether inclusion of abnormal levels of circulating cardiac biomarkers (alone or together) improved the discriminatory abilities of models 2 and 3 for the primary outcome. Although it has been suggested that the more objective way to compare across studies is to use the continuous NRI version, we have also performed a sensitivity analysis with categorical NRI analysis for completeness, applying a conservative approach considering many cutoffs (\<10, 10--20, 20--30, 30--50, and \>50%), to solve the issues regarding the absence of standard risk thresholds in diabetes, heterogeneity of the population studied, and existence of different meaningful categories for the considered outcome.

In order to compare cardiac biomarkers and conventional measures of diabetes complications on the same scale, using Cox regression models we estimated hazard ratios (HRs) corresponding with a change of 1 SD for parameters with a continuous distribution (UACR, eGFR, TnT, and NTproBNP), maintaining dichotomous variables for retinopathy, PAD, and ECG abnormalities. To allow for flexible, potentially nonlinear relationships, we utilized restricted cubic spline models ([@B38]) applied to a fully adjusted model. Furthermore, to assess whether the prognostic relevance of the considered biomarkers may be a simple surrogate for renal dysfunction, we performed a sensitivity analysis excluding patients with eGFR \<60 mL/min/1.73 m^2^. For all analyses, two-sided *P* values of \<0.05 were considered statistically significant. No adjustments were made for multiple comparisons. All analyses were performed using Stata, version 13 (StataCorp, College Station, TX).

Results {#s6}
=======

Baseline Characteristics According to Markers of Risk in Diabetes (Conventional/ECG Versus Cardiac Biomarkers) {#s7}
--------------------------------------------------------------------------------------------------------------

Clinical characteristics significantly differed across the four categories of participants with diabetes ([Table 1](#T1){ref-type="table"}). Out of 26 characteristics considered, 19 were nominally statistically significant. Participants in group II (only conventional complications/abnormal ECG) were more commonly African American. Conversely, participants in group III (abnormal circulating cardiac biomarkers alone) were more commonly white, less frequently hypertensive, had the lowest use of therapies for diabetes and antihypertension and lipid-lowering therapy, and had shorter duration of diabetes. Finally, participants in group IV (both abnormal cardiac biomarker and conventional complication/abnormal ECG) were more commonly men, were more hypertensive, and had higher prevalence of treatments directed against risk factors and the longest duration of diabetes.

###### 

Baseline characteristics of ARIC participants with diabetes, without prevalent HF, CHD, and stroke, by categories of conventional diabetes complications/ECG/cardiac biomarker

                                                 Overall           No markers of risk   Only conventional/ECG                             Only cardiac biomarker                                                          Both                                                                                                               *P*
  ---------------------------------------------- ----------------- -------------------- ------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ ---------
  *n* (%)                                        1,510             725 (48)             356 (24)                                          186 (12)                                                                        243 (16)                                                                                                           
  Age (years)                                    63 ± 6            62 ± 5               62 ± 5                                            65 ± 6[\*](#t1n3){ref-type="table-fn"}[\^](#t1n4){ref-type="table-fn"}          65 ± 6[\*](#t1n3){ref-type="table-fn"}[\^](#t1n4){ref-type="table-fn"}                                             \<0.001
  Female                                         52                51                   61[\*](#t1n3){ref-type="table-fn"}                49[\^](#t1n4){ref-type="table-fn"}                                              44[\^](#t1n4){ref-type="table-fn"}                                                                                 \<0.001
  African American                               31                29                   43[\*](#t1n3){ref-type="table-fn"}                19[\*](#t1n3){ref-type="table-fn"}[\^](#t1n4){ref-type="table-fn"}              30[\^](#t1n4){ref-type="table-fn"}[\#](#t1n5){ref-type="table-fn"}                                                 \<0.001
  BMI (kg/m^2^)                                  31.2 ± 5.8        31.0 ± 5.7           31.5 ± 6.1                                        31.3 ± 5.9                                                                      31.0 ± 5.3                                                                                                         0.67
  Waist-to-hip ratio                             0.98 ± 0.06       0.97 ± 0.06          0.98 ± 0.06                                       0.98 ± 0.07                                                                     0.98 ± 0.06                                                                                                        0.20
  Low education[‡](#t1n1){ref-type="table-fn"}   25                21                   31[\*](#t1n3){ref-type="table-fn"}                17[\^](#t1n4){ref-type="table-fn"}                                              32[\*](#t1n3){ref-type="table-fn"}[\#](#t1n5){ref-type="table-fn"}                                                 \<0.001
  Cigarettes (pack-years)                        2 (0, 26)         1 (0, 24)            1 (0, 26)                                         6 (0, 26)                                                                       3 (0, 34)                                                                                                          0.40
  Hypertension[†](#t1n2){ref-type="table-fn"}    60                50                   68[\*](#t1n3){ref-type="table-fn"}                59[\^](#t1n4){ref-type="table-fn"}                                              76[\*](#t1n3){ref-type="table-fn"}[\^](#t1n4){ref-type="table-fn"}[\#](#t1n5){ref-type="table-fn"}                 \<0.001
  SBP (mmHg)                                     132 ± 18          128 ± 16             134 ± 18[\*](#t1n3){ref-type="table-fn"}          132 ± 18                                                                        139 ± 23[\*](#t1n3){ref-type="table-fn"}[\^](#t1n4){ref-type="table-fn"}[\#](#t1n5){ref-type="table-fn"}           \<0.001
  DBP (mmHg)                                     71 ± 10           71 ± 9               71 ± 11                                           70 ± 11                                                                         70 ± 12                                                                                                            0.85
  Antihypert. Rx                                 57                47                   64[\*](#t1n3){ref-type="table-fn"}                57[\*](#t1n3){ref-type="table-fn"}                                              77[\*](#t1n3){ref-type="table-fn"}[\^](#t1n4){ref-type="table-fn"}[\#](#t1n5){ref-type="table-fn"}                 \<0.001
  Triglyceride (mg/dL)                           142 (100, 206)    137 (100, 203)       148 (101, 206)                                    139 (103, 205)                                                                  142 (103, 213)                                                                                                     0.41
  LDL (mg/dL)                                    122 ± 34          125 ± 34             122 ± 34                                          119 ± 30                                                                        118 ± 38                                                                                                           0.042
  Total-to-HDL chol. ratio                       4.8 ± 1.6         4.8 ± 1.4            4.8 ± 1.6                                         4.8 ± 1.6                                                                       4.9 ± 1.9                                                                                                          0.75
  Lipid-lowering Rx                              16                16                   16                                                10[\^](#t1n4){ref-type="table-fn"}                                              23[\*](#t1n3){ref-type="table-fn"}[\#](#t1n5){ref-type="table-fn"}                                                 0.002
  Aspirin Rx                                     56                54                   56                                                58                                                                              59                                                                                                                 0.48
  Creatinine (mg/dL)                             0.89 ± 0.57       0.84 ± 0.18          0.85 ± 0.24                                       0.86 ± 0.18                                                                     1.13 ± 1.33[\*](#t1n3){ref-type="table-fn"}[\^](#t1n4){ref-type="table-fn"}[\#](#t1n5){ref-type="table-fn"}        \<0.001
  eGFR (mL/min/1.73 m^2^)                        93 ± 19           98 ± 14              94 ± 20[\*](#t1n3){ref-type="table-fn"}           91 ± 14[\*](#t1n3){ref-type="table-fn"}                                         79 ± 24[\*](#t1n3){ref-type="table-fn"}[\^](#t1n4){ref-type="table-fn"}[\#](#t1n5){ref-type="table-fn"}            \<0.001
  UACR (mg/g)                                    4.3 (1.5, 12.9)   3.0 (1.2, 6.7)       7.5 (2.0, 45.6)[\*](#t1n3){ref-type="table-fn"}   4.2 (1.7, 8.6)                                                                  17.6 (4.0, 90.9)[\*](#t1n3){ref-type="table-fn"}[\^](#t1n4){ref-type="table-fn"}[\#](#t1n5){ref-type="table-fn"}   \<0.001
  Glucose (mg/dL)                                137 (117, 180)    133 (116, 170)       151 (126, 209)[\*](#t1n3){ref-type="table-fn"}    134 (113, 168)[\^](#t1n4){ref-type="table-fn"}                                  135 (116, 177)                                                                                                     \<0.001
  Longer diabetes duration^ç^                    38                31                   44[\*](#t1n3){ref-type="table-fn"}                37[\^](#t1n4){ref-type="table-fn"}                                              51[\*](#t1n3){ref-type="table-fn"}[\^](#t1n4){ref-type="table-fn"}[\#](#t1n5){ref-type="table-fn"}                 \<0.001
  Drug therapy for diabetes                      44                36                   53[\*](#t1n3){ref-type="table-fn"}                38[\^](#t1n4){ref-type="table-fn"}                                              57[\*](#t1n3){ref-type="table-fn"}[\^](#t1n4){ref-type="table-fn"}[\#](#t1n5){ref-type="table-fn"}                 \<0.001
  Insulin                                        15                9                    23[\*](#t1n3){ref-type="table-fn"}                10[\^](#t1n4){ref-type="table-fn"}                                              26[\*](#t1n3){ref-type="table-fn"}[\#](#t1n5){ref-type="table-fn"}                                                 \<0.001
  ABI                                            1.14 ± 0.16       1.18 ± 0.13          1.08 ± 0.19[\*](#t1n3){ref-type="table-fn"}       1.18 ± 0.14[\^](#t1n4){ref-type="table-fn"}                                     1.10 ± 0.19[\*](#t1n3){ref-type="table-fn"}[\#](#t1n5){ref-type="table-fn"}                                        \<0.001
  hs-TnT (ng/L)                                  6 (3, 10)         5 (3, 7)             6 (3, 8)                                          10 (5, 17)[\*](#t1n3){ref-type="table-fn"}[\^](#t1n4){ref-type="table-fn"}      14 (7, 20)[\*](#t1n3){ref-type="table-fn"}[\^](#t1n4){ref-type="table-fn"}[\#](#t1n5){ref-type="table-fn"}         \<0.001
  NTproBNP (pg/mL)                               54 (25, 107)      39 (20, 67)          43 (23, 73)                                       149 (51, 212)[\*](#t1n3){ref-type="table-fn"}[\^](#t1n4){ref-type="table-fn"}   192 (120, 356)[\*](#t1n3){ref-type="table-fn"}[\^](#t1n4){ref-type="table-fn"}[\#](#t1n5){ref-type="table-fn"}     \<0.001
  Retinopathy                                    13                                     35                                                                                                                                32                                                                                                                 
  Nephropathy                                    19                                     40                                                                                                                                58                                                                                                                 
  PAD                                            8                                      25                                                                                                                                16                                                                                                                 
  Abnormal ECG                                   12                                     22                                                                                                                                41                                                                                                                 
  NTproBNP \>125 pg/mL                           20                                                                                       65                                                                              74                                                                                                                 
  TnT ≥14 ng/L                                   14                                                                                       43                                                                              52                                                                                                                 

Data are mean ± SD, median (25th, 75th percentiles), or percentage unless otherwise indicated. Retinopathy: ≥1 sign of retinopathy according to Early Treatment Diabetic Retinopathy Study severity scale. Nephropathy: eGFR \<60 mL/min/1.73 m^2^ or albuminuria ≥30 mg/g. PAD: ABI \<0.9 at visit 4 (or 1 or 3 if not available at visit 4), hospitalization for PAD prior to visit 4, or intermittent claudication symptoms at follow-up questionnaire before visit 4. ECG abnormalities: ventricular conduction defect, left ventricular hypertrophy, isolated major ST-T wave abnormalities, or presence of atrial fibrillation. Antihypert., antihypertension; chol., cholesterol; DBP, diastolic blood pressure; Rx, prescription; SBP, systolic blood pressure.

‡Low education level defined as less than high school degree.

^ç^Longer duration of diabetes: disease diagnosed at the first ARIC study visit.

†Hypertension defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or current use of any antihypertension medications.

\**P* \< 0.05 compared with absence of all markers/measures.

\^*P* \< 0.05 compared with only conventional measures/abnormal ECG.

\#*P* \< 0.05 compared with only cardiac biomarkers.

Cardiovascular Risk in Subjects With Diabetes Compared With Subjects Without Diabetes {#s8}
-------------------------------------------------------------------------------------

Over a median follow-up time of 13.1 years (25th, 75th percentiles 6.9, 14.4), an incident CVD event occurred in 540 (36%) participants with diabetes and in 1,331 (19%) participants without diabetes. Compared with subjects without diabetes, in multivariable models adjusted for demographics and traditional cardiovascular risk factors (model 2) participants with diabetes had a higher risk of incident CVD event (HR 1.60 \[95% CI 1.44--1.79\], *P* \< 0.001). However, subjects with diabetes with normal cardiac biomarkers, normal ECG, and no conventional diabetes complications (group I) had only a mildly increased risk of events (1.12 \[0.95--1.31\], *P* = 0.18), while people with conventional complications/abnormal ECG alone (group II) had ∼1.5-fold higher risk of incident CVD (1.68 \[1.39--2.02\], *P* \< 0.001). Similarly, participants in group III (abnormal circulating cardiac biomarkers alone) had ∼2.0-fold higher risk (1.99 \[1.59--2.50\], *P* \< 0.001), while subjects in group IV (combined abnormality of cardiac biomarker and conventional diabetes complication/ECG) had a 3.0-fold higher risk (2.80 \[2.34--3.35\], *P* \< 0.001) ([Fig. 1](#F1){ref-type="fig"}).

![Kaplan-Meier curves for probability of fatal and nonfatal cardiovascular events. HRs are adjusted for demographic characteristics and cardiovascular risk factors. DM, diabetes.](dc151760f1){#F1}

Cardiovascular Risk Associated With Individual Markers {#s9}
------------------------------------------------------

Dichotomous indicators of retinopathy, nephropathy, PAD, ECG abnormalities, elevated NTproBNP, and elevated TnT were individually associated with significantly increased risks of CVD when accounting for age, sex, race, and field center (model 1). However, with simultaneous adjustment for traditional cardiovascular risk factors and all six markers (model 4), retinopathy, nephropathy, ECG abnormalities, and elevated cardiac biomarkers remained significantly associated with increased risks for CVD, while PAD was not ([Fig. 2](#F2){ref-type="fig"}). The prognostic relevance of cardiac biomarkers was confirmed looking at the risk associated with 1 SD change of UACR (log transformed) and eGFR, even when tested with restricted cubic spline models ([Supplementary Table 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc15-1760/-/DC1) and [Supplementary Fig. 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc15-1760/-/DC1)). The results were similar in a sensitivity analysis excluding coronary revascularization as a component of the CHD outcome or adjusting model 2 for glycated hemoglobin assessed at visit 2 (data not shown). Additionally, when cIMT was considered as a conventional measure of diabetes complications, this marker was also significantly associated with the primary outcome in fully adjusted analysis ([Supplementary Fig. 2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc15-1760/-/DC1)).

![Forest plot of HRs for the primary outcome of fatal/nonfatal cardiovascular events for each conventional measure of diabetes complications, abnormal ECG, and cardiac biomarkers with hierarchical adjustment across models. adj., adjusted; CV, cardiovascular.](dc151760f2){#F2}

Multivariable models adjusted for traditional cardiovascular risk factors as well as all six markers (model 4) were repeated for the individual components of the primary outcome, i.e., HF, CHD, and stroke ([Fig. 3](#F3){ref-type="fig"}). The only marker consistently associated with increased risk for each of these secondary outcomes was TnT.

![Forest plot of HRs (from models fully adjusted: model 4) for the secondary outcomes of HF (*A*), CHD (*B*), and stroke events (*C*) for each conventional measure of diabetes complications, abnormal ECG, and cardiac biomarkers in ARIC participants with diabetes.](dc151760f3){#F3}

Incremental Prognostic Value of Circulating Cardiac Biomarkers {#s10}
--------------------------------------------------------------

Abnormal levels of circulating cardiac biomarkers improved the discriminatory ability of traditional cardiovascular risk factors (model 2), conventional markers of complications of diabetes, and abnormal ECG (model 3), as shown by modest increases in Harrell *C* statistic, and significant improvement in continuous NRI and IDI statistics ([Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}), with a similar additive value provided by each cardiac biomarker ([Table 2](#T2){ref-type="table"}). As compared with the continuous NRI analysis with categorical biomarkers, results were generally consistent in the sensitivity analyses incorporating log-transformed NTproBNP and hs-TnT as linear predictors and in the categorical NRI ([Supplementary Table 2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc15-1760/-/DC1)), even though we found that using continuous log-transformed biomarkers gave slightly stronger results, while using categorical NRI gave slightly weaker results. Adding cIMT to conventional measures of diabetes complications did not result in discrimination improvement ([Supplementary Table 3](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc15-1760/-/DC1)). A sensitivity analysis conducted excluding patients with eGFR \<60 mL/min/1.73 m^2^ produced nearly identical results (data not shown).

###### 

Reclassification and discrimination statistics (95% CI) for 10-year risk of the primary outcome (fatal and nonfatal HF, CHD, or stroke) by circulating cardiac biomarkers among ARIC participants with diabetes

                                  *C* statistic                         IDI                                NRI
  ------------------------------- ------------------------------------- ---------------------------------- ----------------------------------
  Model 2                         0.668 (0.645--0.691)                                                     
  Model 2 + hs-TnT                0.687 (0.665--0.709) (*P* = 0.001)    0.04 (0.02--0.06) (*P* \< 0.001)   0.11 (0.03--0.18) (*P* = 0.007)
  Model 2 + NTproBNP              0.682 (0.659--0.704) (*P* = 0.009)    0.02 (0.01--0.04) (*P* \< 0.001)   0.11 (0.04--0.17) (*P* = 0.013)
  Model 2 + hs-TnT and NTproBNP   0.694 (0.672--0.716) (*P* \< 0.001)   0.05 (0.03--0.08) (*P* \< 0.001)   0.20 (0.11--0.26) (*P* \< 0.001)
  Model 3                         0.688 (0.665--0.710)                                                     
  Model 3 + hs-TnT                0.698 (0.676--0.720) (*P* = 0.018)    0.02 (0.01--0.04) (*P* \< 0.001)   0.07 (0.00--0.15) (*P* = 0.06)
  Model 3 + NTproBNP              0.694 (0.672--0.716) (*P* = 0.08)     0.01 (0.00--0.02) (*P* \< 0.001)   0.09 (0.03--0.16) (*P* = 0.013)
  Model 3 + hs-TnT and NTproBNP   0.703 (0.681--0.725) (*P* = 0.004)    0.03 (0.02--0.05) (*P* \< 0.001)   0.16 (0.07--0.22) (*P* \< 0.001)

Model 2 adjusted for age, sex, race, center, smoking status, log-transformed pack-years of cigarettes (packs of cigarettes smoked per day times number of years smoked), BMI, waist-to-hip ratio, mean systolic blood pressure, hypertension medication use, lipid-lowering medication use, aspirin use, education level, total-to-HDL cholesterol ratio, log-transformed triglycerides, and duration of disease. Model 3 adjusted for variables in model 2 plus ECG abnormalities and conventional complications of diabetes (retinopathy, nephropathy, PAD).

###### 

Reclassification and discrimination statistics (95% CI) for 10-year risk of each secondary outcome (HF, CHD, or stroke) by circulating cardiac biomarkers among ARIC participants with diabetes

                                  *C* statistic                        IDI                                NRI
  ------------------------------- ------------------------------------ ---------------------------------- ----------------------------------
  HF events (*n* = 317)                                                                                   
   Model 3                        0.747 (0.719--0.774)                                                    
   Model 3 + cardiac biomarkers   0.768 (0.742--0.794) (*P* = 0.004)   0.04 (0.01--0.07) (*P* = 0.007)    0.22 (0.06--0.30) (*P* = 0.027)
  CHD events (*n* = 321)                                                                                  
   Model 3                        0.692 (0.664--0.719)                                                    
   Model 3 + cardiac biomarkers   0.703 (0.675--0.730) (*P* = 0.09)    0.02 (0.01--0.05) (*P* \< 0.001)   0.14 (0.05--0.22) (*P* \< 0.001)
  Stroke events (*n* = 128)                                                                               
   Model 3                        0.741 (0.697--0.784)                                                    
   Model 3 + cardiac biomarkers   0.749 (0.706--0.791) (*P* = 0.35)    0.02 (0.00--0.07) (*P* \< 0.001)   0.22 (0.03--0.32) (*P* = 0.027)

Model 3 adjusted for variables in model 2 (age, sex, race, center, smoking status, log-transformed pack-years of cigarettes \[packs of cigarettes smoked per day times number of years smoked\], BMI, waist-to-hip ratio, mean systolic blood pressure, hypertension medication use, lipid-lowering medication use, aspirin use, education level, total-to-HDL cholesterol ratio, log-transformed triglycerides, and duration of disease) plus ECG abnormalities and conventional complications of diabetes (retinopathy, nephropathy, PAD).

Conclusions {#s11}
===========

Among participants of the ARIC study with prevalent diabetes, there was substantial heterogeneity in the risk of incident CVD. The presence or absence of abnormal levels of circulating cardiac biomarkers aided in the differentiation of individuals with diabetes at the greatest or lowest risk of events, respectively. Importantly, the inclusion of cardiac biomarkers significantly improved CVD risk assessment in persons with diabetes above and beyond factors currently used in clinical practice, such as traditional cardiovascular risk factors, ECG abnormalities, and conventional measures of diabetes complications. Collectively, these findings may help refine risk stratification and potentially inform clinical management recommendations regarding CVD prevention strategies among individuals with diabetes.

Comparison With Previous Data {#s12}
-----------------------------

The prognostic importance of TnT and NTproBNP has previously been shown in the general population ([@B5],[@B6]). However, relatively few data are available in persons with diabetes. Small studies of clinically referred patients ([@B7]--[@B9]) and one prospective population-based study ([@B12]) have shown a role for NTproBNP as a marker of CVD risk in subjects with diabetes. Another community study of women described the prognostic relevance of hs-TnT in subjects with diabetes ([@B10]). These prior evaluations demonstrated the predictive value of cardiac biomarkers for cardiovascular disease; however, whether circulating biomarkers added incremental value to existing risk factors was not examined. One recent study of persons with diabetes evaluated both troponin and NTproBNP in their ability to reclassify CVD and mortality risk ([@B11]). However, this study was a post hoc analysis of a randomized trial, which may lack applicability to the broader population, and the authors considered a population at higher risk, including also subjects with a known history of MI, stroke, or HF at baseline. Furthermore, in contrast to the study by Hillis et al. ([@B11]), we also used a threshold response analysis and examined the incidence of HF, which is increasingly recognized as an important end point in diabetes.

Our results in ARIC extend the observations from all prior studies. We included a broad community-based middle-aged population of individuals with diabetes. The risk of incident CVD was examined over \>10 years of follow-up. NTproBNP and hs-TnT were analyzed both as categorical variables, according to well-known cutoffs to facilitate clinical application, and as continuous variables with similar results. The robustness of our findings regarding cardiac biomarkers was further supported by the demonstration of additive value for CVD risk prediction beyond established cardiovascular risk factors included in the Framingham risk model and conventional diabetes complications, including retinopathy, a potent predictor of adverse CVD outcomes.

Clinical Implications {#s13}
---------------------

The increased risk for CVD in diabetes causes a growing economic and public health burden. Despite improvements in risk factor control, recently it has been shown that almost half of U.S. adults with diabetes did not meet the recommended goals for diabetes care ([@B39]). Furthermore, we encountered a wide heterogeneity of CVD risk in diabetes, as recently suggested ([@B2]--[@B4]). The suboptimal implementation of preventive strategies and heterogeneity in risk emphasizes the need to refine CVD risk stratification to better identify higher- and lower-risk individuals with diabetes. Our findings may help to inform clinical decisions regarding recommendations for preventive strategies, e.g., intensity of statin therapy and aspirin use ([@B1]). While regular screening for retinopathy, nephropathy, PAD, and ECG abnormalities is recommended in persons with diabetes ([@B1]), our results suggest that measurement of NTproBNP and TnT may be incrementally informative among individuals with diabetes. Importantly, the absence of all these six markers identified a subject with diabetes (prevalence 48% in this study population) with a low risk of incident CVD events. In contrast, 12% of the study population had high values of cardiac biomarkers alone. Compared with the other categories of diabetes complications, this subgroup was characterized by a lower burden of cardiovascular risk factors and shorter duration of diabetes. Nonetheless, elevated cardiac biomarkers were associated with higher risk of incident cardiovascular events, which may justify intensive multifactorial interventions to reduce diabetes-related CVD risk, although this theory remains to be tested. Furthermore, it is conceivable that cardiac biomarkers may be used as screening tests to detect individuals with diabetes more suitable for comprehensive assessment of silent heart disease, such as echocardiography and stress testing, as recently suggested ([@B40]).

Finally, contemporary data further underscore the clinical utility of cardiac biomarkers, not only to risk stratify subjects with diabetes, but also to select appropriate therapy and to guide its optimization. Recently, it had been shown that accelerated uptitration of renin angiotensin system antagonists and β-blockers to maximum tolerated dosages was an effective and safe intervention for the primary prevention of cardiac events in patients with diabetes preselected using NTproBNP ([@B41]). Furthermore, in the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus--Thrombolysis in Myocardial Infarction (SAVOR-TIMI 53) trial, which enrolled patients with diabetes and a history or risk of cardiovascular events, the rates of hospital admission for HF were significantly higher with saxagliptin than with placebo in patients with the highest concentrations of NTproBNP at study baseline ([@B42]). These data suggest that the choice of antihyperglycemic agents in patients at risk for developing HF may also be guided by cardiac biomarkers.

Some limitations of this analysis should be noted. First, ABI in ARIC was measured only on one leg and upper extremity. Furthermore, ABI data for some participants were obtained antecedent to visit 4, while retinal photography was performed at visit 3. This may have led to a possible underestimation of the risk associated with these measures of diabetes complications. Second, residual confounding remains a possibility. For example, in the ARIC study echocardiography was performed only in African Americans at visit 3 (1993--1995). Thus, we did not adjust for this variable in our analysis, which used visit 4 (1996--1998) as baseline. Finally, statin prescription was low at baseline in this cohort, according to guidelines at the time of ARIC visit 4. However, the identification of a subgroup of participants with diabetes, but low incidence of CVD over a long follow-up period despite low statin prescription at the beginning, further underscores the heterogeneity in diabetes and the necessity of individualizing treatment strategies.

In conclusion, in a community sample of middle-aged individuals with diabetes abnormal levels of cardiac biomarkers were significantly associated with increased CVD risk and provided incremental risk prediction over traditional cardiovascular risk factors, abnormal ECG, and conventional measures of diabetes complications. We encountered a wide range of CVD risk in diabetes, and our data suggest that one way to help distinguish high from low risk is to risk stratify according to cardiac biomarkers.

Supplementary Material
======================

###### Supplementary Data

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc15-1760/-/DC1>.
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